Amelanotic melanoma

Summary

Amelanotic melanoma (MONDO:0002971) is a cancer. A subtype of melanoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	amelanotic melanoma
Mondo ID	MONDO:0002971
EFO	EFO:1001937
MeSH	D018328
DOID	DOID:4359
NCIT	C3802
UMLS	C0206735
MedGen	64644
Is cancer (heuristic)	yes

Also known as: amelanotic melanoma · amelanotic melanoma (morphologic abnormality) · amelanotic melanomas · melanoma, amelanotic, malignant · melanomas, amelanotic

Data availability: 164 cell lines.

Disease family

This is a subtype of melanoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › melanocytic neoplasm › melanoma › amelanotic melanoma

Related subtypes (14): scrotum melanoma, epithelioid cell melanoma, malignant breast melanoma, melanomatosis, cutaneous melanoma, metastatic melanoma, non-cutaneous melanoma, ocular melanoma, spindle cell melanoma, mixed epithelioid and spindle cell melanoma, malignant melanoma of the mucosa, familial melanoma, CDK4 linked melanoma, childhood malignant melanoma

Subtypes (1): amelanotic skin melanoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.